Her appointment has been planned to coincide with the company’s developing emphasis on the commercialisation of its genetically modified AquAdvantage Salmon, now that a number of key regulatory hurdles have been cleared.
“AquAdvantage Salmon is the type of innovation necessary to meet the rising consumer demand for a healthy source of protein, and salmon in particular, without placing further pressure on the sea and coastal environments. I look forward to working with Dr Stotish and the team to successfully commercialise it both in North America and abroad,” said Wulf.
Dr Stotish, AquaBounty’s current CEO, will move to a role as executive director, with responsibility for research and regulatory affairs. He will continue to work closely with the regulatory authorities involved in food and biotechnology in the United States, Canada, and other countries. He will also lead the continued technical development of new products and will work closely with Wulf in the planned expansion of the production organization both within North America and abroad.
Richard Clothier, chairman of the board, said: “We are delighted to appoint Sylvia Wulf as the chief executive officer of AquaBounty. Her wide and deep experience in the food industry in North America and its fish sector will be a vital asset in the production and marketing of AquAdvantage Salmon and in the development of additional products. This appointment greatly strengthens AquaBounty’s executive team at a crucial stage in the company’s development, and the board looks forward to a period of rapid growth under Sylvia’s leadership.
“The board would also like to take this opportunity to thank Dr Stotish for the tireless work and effort he has put into successfully navigating the Company through the rigorous regulatory channels in the United States and Canada that culminated in approvals for AquAdvantage Salmon by both the US Food and Drug Administration and Health Canada.”